{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:15Z","timestamp":1793121495899,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In EPCORE NHL-1, the CD3 \u00d7 CD20 bispecific antibody epcoritamab demonstrated promising efficacy and manageable safety in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) after \u22652 prior lines of therapy. Using the clonoSEQ assay, we evaluated minimal residual disease (MRD) status using peripheral blood mononuclear cells (PBMCs) and\/or circulating tumor DNA (ctDNA) at prespecified time points and investigated their correlation with clinical outcomes. Epcoritamab induced rapid conversion to MRD negativity, with most MRD-evaluable patients reaching MRD negativity by cycle 3 (C3) day 1 (D1) as measured by either analyte. MRD negativity at C3D1 landmark by either analyte correlated with prolonged progression-free survival (PFS; median not reached), irrespective of radiographic response status. PFS was comparable among patients with overall MRD negativity by PBMCs or ctDNA, regardless of challenging-to-treat disease features. By C3D1 and C5D1 landmarks, patients with complete or partial response, as assessed by positron emission tomography\/computed tomography (PET\/CT), who were MRD positive had a shorter PFS compared with those who were MRD negative. In multivariable analyses at week 12 and week 18 PET\/CT landmarks, MRD-negative responders by PBMC assessment (week 12) and by both PBMC and ctDNA assessment (week 18) had significantly improved PFS when adjusted for baseline clinical risk factors. These analyses demonstrate that MRD negativity is associated with rapid molecular responses to epcoritamab and prolonged PFS in patients with R\/R FL, underscoring the value of MRD analysis to complement conventional response assessment. These findings may aid future clinical trial design or clinical practice in FL. This trial was registered at www.clinicaltrials.gov as NCT03625037.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017565","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:30:43Z","timestamp":1783726243000},"page":"6381-6394","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R\/R FL"],"prefix":"10.1182","volume":"10","author":[{"given":"I\u015f\u0131l","family":"Alt\u0131nta\u015f","sequence":"first","affiliation":[{"name":"1Genmab, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Morehouse","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Favaro","sequence":"additional","affiliation":[{"name":"3Genmab, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rana","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Karavitis","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[{"name":"4AbbVie Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zhao","sequence":"additional","affiliation":[{"name":"4AbbVie Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-1548","authenticated-orcid":false,"given":"Kim","family":"Linton","sequence":"additional","affiliation":[{"name":"5The Christie NHS Foundation Trust, Manchester Cancer Research Centre and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[{"name":"6City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-3838","authenticated-orcid":false,"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[{"name":"8Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5044","authenticated-orcid":false,"given":"Jessica","family":"Okosun","sequence":"additional","affiliation":[{"name":"9Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2919-8343","authenticated-orcid":false,"given":"Mark","family":"Fereshteh","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jure-Kunkel","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7902-2522","authenticated-orcid":false,"given":"David","family":"Soong","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Steele","sequence":"additional","affiliation":[{"name":"2Genmab, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"1","key":"2026101310430042700_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2026101310430042700_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cancers15030785","article-title":"Follicular lymphoma in the 5th edition of the WHO-classification of haematolymphoid neoplasms\u2014updated classification and new biological data","volume":"15","author":"Kurz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026101310430042700_bib3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"2026101310430042700_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026101310430042700_bib5","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/bloodadvances.2020002724","article-title":"Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials","volume":"5","author":"Casulo","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2026101310430042700_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2026101310430042700_bib7","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101310430042700_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.2852","article-title":"Upfront identification of high-risk follicular lymphoma","volume":"39","author":"Casulo","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"2026101310430042700_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ejh.14335","article-title":"Comparative analysis of bispecific antibodies and CAR T-cell therapy in follicular lymphoma","volume":"114","author":"Morabito","year":"2025","journal-title":"Eur J Haematol"},{"key":"2026101310430042700_bib10","doi-asserted-by":"crossref","first-page":"101099","DOI":"10.1016\/j.blre.2023.101099","article-title":"Thinking \u201coutside the germinal center\u201d: re-educating T cells to combat follicular lymphoma","volume":"61","author":"Thiruvengadam","year":"2023","journal-title":"Blood Rev"},{"key":"2026101310430042700_bib11","doi-asserted-by":"crossref","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"issue":"8","key":"2026101310430042700_bib12","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026101310430042700_bib13","unstructured":"U.S. Food and Drug Administration\n          . FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Accessed 7 February 2025. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b-cell."},{"key":"2026101310430042700_bib14","volume-title":"TEPKINLY (epcoritamab) for subcutaneous injection. Package insert","year":"2024"},{"key":"2026101310430042700_bib15","volume-title":"EPKINLY (epcoritamab-bysp) for subcutaneous injection. Package insert","year":"2024"},{"key":"2026101310430042700_bib16","volume-title":"EPKINLY (epcoritamab) for subcutaneous injection. Japan package insert","year":"2023"},{"key":"2026101310430042700_bib17","unstructured":"Epkinly injection\n          . Prescribing information. U.S. Food and Drug Administration. Accessed 27 November 2025. https:\/\/www.genmab-pi.com\/prescribing-information\/epkinly-pi.pdf."},{"issue":"10524","key":"2026101310430042700_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"},{"issue":"32","key":"2026101310430042700_bib19","first-page":"1","article-title":"Minimal residual disease in follicular lymphoma","volume":"5","author":"Pott","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"15","key":"2026101310430042700_bib20","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2024026978","article-title":"End points and outcomes in follicular lymphoma: what should we measure, how, and why?","volume":"146","author":"Di","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026101310430042700_bib21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"issue":"23","key":"2026101310430042700_bib22","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101310430042700_bib23","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood-2023-181813","article-title":"MRD monitoring by euroclonality IGH based NGS approach predicts outcome in follicular lymphoma patients lacking a conventional BCL2::IGH marker: a substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 trial [abstract]","volume":"142","author":"Genuardi","year":"2023","journal-title":"Blood"},{"issue":"27","key":"2026101310430042700_bib24","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026101310430042700_bib25","first-page":"375","article-title":"A prognostic model for relapse in patients with follicular lymphoma treated with immunochemotherapy using baseline metabolic tumor volume and interim PET","volume":"61","author":"Cottereau","year":"2020","journal-title":"J Nucl Med"},{"issue":"suppl 6","key":"2026101310430042700_bib26","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1158\/1538-7445.AM2024-5071","article-title":"Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (pts) with relapsed\/refractory follicular lymphoma (R\/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1\/2 EPCORE\u2122 NHL-1 trial [abstract]","volume":"84","author":"Soong","year":"2024","journal-title":"Cancer Res"},{"issue":"12","key":"2026101310430042700_bib27","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1111\/cas.15996","article-title":"Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma","volume":"114","author":"Izutsu","year":"2023","journal-title":"Cancer Sci"},{"issue":"9","key":"2026101310430042700_bib28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.clml.2024.04.009","article-title":"Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease","volume":"24","author":"Chauhan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026101310430042700_bib29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fonc.2019.00528","article-title":"The minimal residual disease in non-Hodgkin's lymphomas: from the laboratory to the clinical practice","volume":"9","author":"Galimberti","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"2026101310430042700_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026101310430042700_bib31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"2026101310430042700_bib32","volume-title":"Adaptive Biotechnologies Corp clonoSEQ\u00ae Test Specimen Requirements. Document NP-US-cSEQ-0174","year":"2025"},{"key":"2026101310430042700_bib33","volume-title":"Adaptive Biotechnologies Corp. clonoSEQ\u00ae Test Specimen Requirements. Document NP-US-cSEQ-0025-2","year":"2021"},{"issue":"suppl 1","key":"2026101310430042700_bib34","first-page":"3885","article-title":"Minimal residual disease (MRD), pharmacokinetic (PK), and pharmacodynamic (PD) assessment of epcoritamab 2- vs 3-step step-up dosing in patients with relapsed\/refractory follicular lymphoma (R\/R FL) [abstract]","volume":"8","author":"Morehouse","year":"2024","journal-title":"HemaSphere"},{"issue":"5","key":"2026101310430042700_bib35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.23.00838","article-title":"Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study","volume":"42","author":"Pott","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026101310430042700_bib36","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood-2023-179612","article-title":"Minimal residual disease (MRD) status predicts outcomes in patients with follicular lymphoma (FL) treated with chemo-immunotherapy on SWOG S0016 [abstract]","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"issue":"28","key":"2026101310430042700_bib37","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026101310430042700_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bjh.19458","article-title":"Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease","volume":"205","author":"Alcoceba","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"2026101310430042700_bib39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Jim\u00e9nez-Ubieto","year":"2023","journal-title":"Leukemia"},{"key":"2026101310430042700_bib40","doi-asserted-by":"crossref","first-page":"1430070","DOI":"10.3389\/fimmu.2024.1430070","article-title":"Minimal residual disease detection in lymphoma: methods, procedures and clinical significance","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6381\/2590334\/blooda_adv-2025-017565-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6381\/2590334\/blooda_adv-2025-017565-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:14Z","timestamp":1791902594000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6381\/569669\/MRD-negativity-by-PBMCs-and-ctDNA-confirms-deep"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017565","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,23]]}}}